Etesian Wealth Advisors Inc. Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

Etesian Wealth Advisors Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,546 shares of the company’s stock after selling 1,244 shares during the period. Etesian Wealth Advisors Inc.’s holdings in Johnson & Johnson were worth $802,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Spirepoint Private Client LLC increased its stake in Johnson & Johnson by 2.8% during the 4th quarter. Spirepoint Private Client LLC now owns 97,116 shares of the company’s stock worth $14,045,000 after buying an additional 2,676 shares in the last quarter. Financial Advocates Investment Management increased its position in shares of Johnson & Johnson by 12.8% during the fourth quarter. Financial Advocates Investment Management now owns 21,029 shares of the company’s stock worth $3,041,000 after purchasing an additional 2,380 shares in the last quarter. Adero Partners LLC raised its stake in Johnson & Johnson by 19.0% in the 4th quarter. Adero Partners LLC now owns 13,233 shares of the company’s stock valued at $1,914,000 after purchasing an additional 2,116 shares during the last quarter. YANKCOM Partnership purchased a new position in Johnson & Johnson in the 4th quarter valued at $923,000. Finally, Centennial Wealth Advisory LLC boosted its stake in Johnson & Johnson by 11.6% during the 4th quarter. Centennial Wealth Advisory LLC now owns 1,968 shares of the company’s stock worth $285,000 after purchasing an additional 204 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JNJ shares. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, January 23rd. Guggenheim increased their price target on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Barclays boosted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Finally, Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Down 0.3 %

Johnson & Johnson stock opened at $153.10 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a 50 day moving average price of $147.42 and a 200 day moving average price of $156.08. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a market capitalization of $368.61 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the business earned $2.29 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.